<DOC>
	<DOCNO>NCT00778375</DOCNO>
	<brief_summary>The goal clinical research study learn clofarabine give combination cytarabine decitabine help control disease patient AML MDS 60 year old old . The safety treatment also study .</brief_summary>
	<brief_title>Clofarabine Plus Low-Dose Cytarabine Induction Decitabine Consolidation Frontline Acute Myeloid Leukemia ( AML ) High-Risk Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>The Study Drugs : Clofarabine design interfere growth development cancer cell . Cytarabine design insert DNA ( genetic material cell ) cancer cell stop DNA repairing . Decitabine design damage DNA cell , may cause cancer cell die . Study Drug Administration : If find eligible take part study , Days 1-5 , receive clofarabine needle vein 1-2 hour . On Days 1-10 , receive cytarabine injection twice day . You may receive 2 cycle dose schedule . There 10 day cycle . Consolidation Cycles : If show response treatment , continue total 17 cycle therapy , call `` consolidation cycle '' . Not every participant may able receive 17 consolidation cycle . The actual number receive depend whether maintain response able tolerate ongoing therapy . There 4-7 week consolidation cycle depend side effect may blood count . For consolidation cycle 1 , 2 , 6 , 7 , 8 , 12 , 13 , 14 , receive clofarabine cytarabine , schedule different . On Days 1-3 receive clofarabine vein . On Days 1-7 , receive cytarabine vein . On day receive clofarabine cytarabine ( Days 1-3 ) , clofarabine give 3-6 hour cytarabine injection . You teach give cytarabine injection . In case , leave clinic receiving clofarabine . You require record injection cytarabine diary unless receive treatment hospital . During consolidation cycle 3-5 , 9-11 , 15-17 , receive decitabine . Decitabine give needle vein 1-2 hour Days 1-5 . During decitabine cycle , may treat home , must return MD Anderson study visit start cycle . If achieve response first 2 cycle treatment clofarabine cytarabine , stay study receive 3 cycle decitabine alone ( dose schedule consolidation course ) . If achieve response 3 decitabine cycle , continue consolidation cycle . If evidence response 3 decitabine cycle , may take study . Study Visits : On Day 1 every cycle , follow test procedure perform : - You physical exam , include measurement weight vital sign . - You performance status evaluation . - Blood ( 1-2 teaspoon ) draw routine test . About 3 week first course , may bone marrow aspirate check status disease . To collect bone marrow aspirate , area hip numb anesthetic , small amount bone marrow withdrawn large needle . After , bone marrow aspirate every 2 week ( often doctor feel necessary ) . If routine blood test indicate still leukemia , may need bone marrow sample collect . You need stay Houston first 5 week treatment . After , need return Houston cycle receive clofarabine treatment . Decitabine-only consolidation cycle give local oncologist . In either case , check-up visit blood test local doctor treatment . Length Study : You stay study 19 cycle . You take study early experience intolerable side effect . You may take study early disease get bad . Follow-up Visits : Once active treatment long still part study , every 3-6 month blood ( 1 tablespoon ) drawn check status disease overall health . This investigational study . Clofarabine FDA approve commercially available use pediatric patient ALL . Its use patient AML experimental . Cytarabine FDA approve commercially available use patient AML . Decitabine FDA approve commercially available use patient MDS , use patient AML investigational . Up 120 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Previously untreated AML highrisk MDS ( &gt; /= 10 % blast &gt; /= IPSS intermediate2 ) . Prior therapy hydroxyurea , biological target therapy ( e.g . flt3 inhibitor , kinase inhibitor , azacitidine ) , hematopoietic growth factor allow . 2 . Age &gt; /= 60 year . 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /= 2 . 4 . Adequate hepatic ( serum total bilirubin &lt; /= 1.5 x ULN , serum glutamate pyruvate transaminase ( SGPT ) and/or serum glutamate oxaloacetate transaminase ( SGOT ) &lt; /= 2.5 x ULN ) renal function ( creatinine &lt; /= 1.5 mg/dL ) . 5 . Sign write informed consent 1 . Cardiac ejection fraction &lt; 40 % . 2 . Prior therapy clofarabine decitabine . 3 . Active uncontrolled disease/infection judge treat physician . 4 . Pregnancy 5 . Acute promyelocytic leukemia ( APL ) . 6 . Women childbearing potential men practice contraception . 7 . Women childbearing potential men must agree use contraception prior study entry duration study participation .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>AML</keyword>
	<keyword>MDS</keyword>
	<keyword>Clofarabine</keyword>
	<keyword>Ara-C</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Decitabine</keyword>
</DOC>